Abstract
Intravesical Bacillus Calmette-Guérin (BCG) immunotherapy decreases the progression risk of non-muscle-invasive bladder cancer, but potentially yields a broad spectrum of side effects. We report the case of a 73-year-old man affected by miliary pulmonary BCG infection, whose microbiological diagnosis was probably hindered by empiric fluoroquinolones, focusing on imaging and clinical work-up.
MeSH terms
-
Aged
-
Antitubercular Agents / therapeutic use
-
BCG Vaccine / adverse effects*
-
Bronchoalveolar Lavage Fluid / microbiology
-
Carcinoma, Transitional Cell / therapy
-
Delayed Diagnosis
-
Fever of Unknown Origin / microbiology
-
Humans
-
Immunotherapy / adverse effects*
-
Male
-
Mycobacterium bovis / isolation & purification
-
Mycobacterium bovis / pathogenicity*
-
Ofloxacin / therapeutic use
-
Sputum / microbiology
-
Tuberculosis, Miliary / diagnosis
-
Tuberculosis, Miliary / drug therapy
-
Tuberculosis, Miliary / etiology*
-
Tuberculosis, Pulmonary / diagnosis
-
Tuberculosis, Pulmonary / diagnostic imaging
-
Tuberculosis, Pulmonary / drug therapy
-
Tuberculosis, Pulmonary / etiology*
-
Urinary Bladder Neoplasms / therapy
Substances
-
Antitubercular Agents
-
BCG Vaccine
-
Ofloxacin